# A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

> **NCT03156101** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen BinDeBio Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Relapsed B-cell Acute Lymphoblastic Leukemia
- Refractory B-cell Acute Lymphoblastic Leukemia
- Relapsed／Refractory B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** BinD19

## Key facts

- **NCT ID:** NCT03156101
- **Lead sponsor:** Shenzhen BinDeBio Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-02
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03156101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03156101, "A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03156101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*